#arterial stiffness

1 article

A bright, minimalist editorial still life on a pale warm-white stone surface, shot from a slightly elevated three-quarter angle in soft natural window light. At center, a small amber glass supplement bottle with a matte cream label, unbranded, sits beside a few loose white capsules. A pair of weathered hands in a light oatmeal linen sleeve, belonging to an older adult, rests gently near the bottle, with a ceramic mug of tea just out of focus. To the right, a clean glass vial and a delicate glass beaker filled with clear liquid catch the light, hinting at laboratory research without any futuristic touch. A small paper notebook with a handwritten simple line graph rising in a gentle curve lies open nearby, along with a sharpened pencil. Scattered at the edges are soft sprigs of dried eucalyptus and a few pale sage-green leaves, adding an organic note. A faint, abstract molecular diagram printed in muted teal ink on a card leans against the bottle, subtle and graphic. The palette is calm and modern: warm ivory, sage green, soft teal, muted amber, and touches of dusty peach. Long, gentle shadows fall across the surface, and the shallow depth of field blurs the background into creamy neutral tones. The composition leaves generous negative space on the left third for headline text. The overall feel is a trendy health and science journal: clean, airy, trustworthy, and quietly sophisticated, with fine film-like grain and true-to-life color. Ultra-detailed, 16:9 landscape.

1,000 mg of Nicotinamide Riboside Daily Raised Blood Cell NAD+ by About 60% in Older Adults, Randomized Trial Finds

BY DR. SYNAPSE · Oct 15, 2026

A 2018 Nature Communications crossover trial tested nicotinamide riboside at 500 mg twice daily (1,000 mg/day) for six weeks in healthy middle-aged and older adults. The supplement was well tolerated and raised NAD+ in blood immune cells by about 60% compared with placebo. Researchers also saw early signals for lower blood pressure and arterial stiffness, which they flagged as ideas for larger trials, not proven benefits. This article explains why NAD+ is thought to fall with age, what the study did, and what it cannot tell us about disease outcomes or longevity.